Glucosamine Evidence | Supplement Intelligence

Evidence is formulation-specific. A meta-analysis of oral glucosamine sulfate found a small-to-moderate reduction in osteoarthritis pain with little effect on joint-space narrowing, while authoritative guidance and other evidence remain inconsistent. Prescription crystalline glucosamine sulfate should not be treated as interchangeable with unspecified glucosamine products.

Studied context

Glucosamine sulfate, glucosamine hydrochloride, and pharmaceutical-grade preparations should not be treated as interchangeable. Dose and formulation are central to evidence interpretation.

Safety context

Large osteoarthritis trials have not identified major safety problems, but glucosamine may affect blood glucose in some people and may increase bleeding risk with warfarin.

Product directness

V-ITADOL lists glucosamine without a published form or dose. Its finished-product effect on osteoarthritis pain or joint function remains unverified.

Products that list this ingredient/category

Primary and authoritative sources

Review-level evidence highlights

Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis (Systematic review and meta-analysis of randomized double-blind placebo-controlled trials; PMID 30566740)

Population/scope: 17 studies for osteoarthritis pain; 4 studies for joint-space narrowing

Evidence scope: Osteoarthritis pain and structural joint-space outcomes

Finding: Glucosamine sulfate showed a small-to-moderate pooled reduction in pain but little evidence of improved joint-space narrowing.

Limitations: Effects were smaller in non-industry studies; results apply to glucosamine sulfate and should not be generalized to unspecified forms or finished products.

Directness: Relevant human evidence · verified 2026-10-02

Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.